{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:30Z","timestamp":1790612190194,"version":"4.1.0"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011821","name":"Ministry of Education \u2013 Kingdom of Saudi Arabi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011821","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40262-022-01169-4","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T02:06:37Z","timestamp":1662170797000},"page":"1365-1392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Altered Bioavailability and Pharmacokinetics in Crohn\u2019s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs"],"prefix":"10.1007","volume":"61","author":[{"given":"Sarah","family":"Alrubia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3917-844X","authenticated-orcid":false,"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380:1590\u2013605.","journal-title":"Lancet"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.mpmed.2011.01.004","volume":"39","author":"AL Hart","year":"2011","unstructured":"Hart AL, Ng SC. Crohn\u2019s disease. Medicine (Baltim). 2011;39:229\u201336.","journal-title":"Medicine (Baltim)"},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/01480549709003891","volume":"20","author":"MM Doherty","year":"1997","unstructured":"Doherty MM, Pang KS. First-pass effect: significance of the intestine for absorption and metabolism. Drug Chem Toxicol. 1997;20:329\u201344.","journal-title":"Drug Chem Toxicol"},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1021\/mp0600687","volume":"4","author":"S Berggren","year":"2007","unstructured":"Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007;4:252\u20137.","journal-title":"Mol Pharm"},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.15585\/mmwr.mm6706a4","volume":"67","author":"F Xu","year":"2018","unstructured":"Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease\u2014United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92:1088\u2013103.","journal-title":"Mayo Clin Proc"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"1169_CR8","unstructured":"FDA. Pharmacokinetics in Patients with Impaired Hepatic Function\u202f: Study Design , Data Analysis , and Impact on Dosing and Labeling. FDA Guid [Internet]. 2003 [cited 2021 Jun 12]; Available from: https:\/\/www.fda.gov\/media\/71311\/download."},{"key":"1169_CR9","unstructured":"FDA. Guidance for industry pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing. FDA Publication. 2020 [cited 2021 Jun 12]; Available from: https:\/\/www.fda.gov\/media\/78573\/download."},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1365-2125.2012.04284.x","volume":"74","author":"AS Darwich","year":"2012","unstructured":"Darwich AS, Henderson K, Burgin A, Ward N, Whittam J, Ammori BJ, et al. Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol. 2012;74:774\u201387.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR11","unstructured":"FDA. Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020 [cited 2021 Jun 20]; Available from: https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugsand\/or."},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/jcph.579","volume":"55","author":"PR Jadhav","year":"2015","unstructured":"Jadhav PR, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V, et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J Clin Pharmacol. 2015;55:1073\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcph.787","volume":"57","author":"IR Younis","year":"2017","unstructured":"Younis IR, Robert Powell J, Rostami-Hodjegan A, Corrigan B, Stockbridge N, Sinha V, et al. Utility of model-based approaches for informing dosing recommendations in specific populations: report from the public AAPS Workshop. J Clin Pharmacol. 2017;57:105\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1169_CR14","unstructured":"Astrazeneca. FDA clinical pharmacology review: Entocort EC (budesonide capsules). 2009 [cited 2021 Oct 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021324s008lbl.pdf."},{"key":"1169_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","volume":"16","author":"EC Fieller","year":"1954","unstructured":"Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B. 1954;16:175\u201385.","journal-title":"J R Stat Soc Ser B"},{"key":"1169_CR16","volume-title":"Intuitive biostatistics: a nonmathematical guide to statistical thinking","author":"H Motulsky","year":"2010","unstructured":"Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. Oxford: Oxford University Press; 2010."},{"key":"1169_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejps.2014.10.018","volume":"67","author":"A Olivares-Morales","year":"2015","unstructured":"Olivares-Morales A, Kamiyama Y, Darwich AS, Aarons L, Rostami-Hodjegan A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur J Pharm Sci. 2015;67:32\u201344.","journal-title":"Eur J Pharm Sci"},{"key":"1169_CR18","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ibd.20389","volume":"14","author":"SS Mahid","year":"2008","unstructured":"Mahid SS, Mulhall AM, Gholson RD, Eichenberger RM, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis. 2008;14:960\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00054725-200311000-00006","volume":"9","author":"SI Reddy","year":"2003","unstructured":"Reddy SI, Burakoff R. Inflammatory bowel disease in African Americans. Inflamm Bowel Dis. 2003;9:380\u20135.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR20","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.e4.","journal-title":"Gastroenterology"},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","volume":"126","author":"EV Loftus","year":"2004","unstructured":"Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504\u201317.","journal-title":"Gastroenterology"},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42.","journal-title":"Gastroenterology"},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/gut.2009.202101","volume":"59","author":"AV Ramadas","year":"2010","unstructured":"Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn\u2019s disease in a population-based cohort from Cardiff (1986\u20132003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200\u20136.","journal-title":"Gut"},{"key":"1169_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/j.1572-0241.2006.00552.x","volume":"101","author":"I Vind","year":"2006","unstructured":"Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkj\u00e6r M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003\u20132005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274\u201382.","journal-title":"Am J Gastroenterol"},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","volume":"114","author":"EV Loftus","year":"1998","unstructured":"Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn\u2019s disease in Olmsted County, Minnesota, 1940\u20131993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161\u20138.","journal-title":"Gastroenterology"},{"key":"1169_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/00365529609006410","volume":"31","author":"B Moum","year":"1996","unstructured":"Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, et al. Incidence of Crohn\u2019s disease in four counties in southeastern Norway, 1990\u201393 a prospective population-based study. Scand J Gastroenterol. 1996;31:355\u201361.","journal-title":"Scand J Gastroenterol"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ibd.21695","volume":"18","author":"A Jussila","year":"2012","unstructured":"Jussila A, Virta LJ, Kautiainen H, Rekiaro M, Nieminen U, F\u00e4rkkil\u00e4 MA. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555\u201361.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","volume":"149","author":"CN Bernstein","year":"1999","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn\u2019s disease and ulcerative colitis in a central Canadian Province: a population-based study. Am J Epidemiol. 1999;149:916\u201324.","journal-title":"Am J Epidemiol"},{"key":"1169_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;1:514.","journal-title":"Lancet"},{"key":"1169_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1976;70:439\u201344.","journal-title":"Gastroenterology"},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"jjw200","DOI":"10.1093\/ecco-jcc\/jjw200","volume":"11","author":"E Zittan","year":"2016","unstructured":"Zittan E, Kabakchiev B, Kelly OB, Milgrom R, Nguyen GC, Croitoru K, et al. Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn\u2019s disease. J Crohns Colitis. 2016;11:jjw200.","journal-title":"J Crohns Colitis"},{"key":"1169_CR32","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.3748\/wjg.14.4127","volume":"14","author":"HJ Freeman","year":"2008","unstructured":"Freeman HJ. Use of the Crohn\u2019s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14:4127.","journal-title":"World J Gastroenterol"},{"key":"1169_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jphp.12928","volume":"71","author":"A Effinger","year":"2019","unstructured":"Effinger A, O\u2019Driscoll CM, McAllister M, Fotaki N. Impact of gastrointestinal disease states on oral drug absorption\u2014implications for formulation design\u2014a PEARRL review. J Pharm Pharmacol. 2019;71:674\u201398.","journal-title":"J Pharm Pharmacol"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1016\/j.xphs.2019.03.018","volume":"108","author":"PJ McNamara","year":"2019","unstructured":"McNamara PJ, Meiman D. Predicting drug binding to human serum albumin and alpha one acid glycoprotein in diseased and age patient populations. J Pharm Sci. 2019;108:2737\u201347.","journal-title":"J Pharm Sci"},{"key":"1169_CR35","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1124\/dmd.114.058404","volume":"42","author":"AS Darwich","year":"2014","unstructured":"Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab Dispos. 2014;42:2016\u201322.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1169_CR37","unstructured":"Certara (Simcyp). Simcyp Simulator Version 19 Help File. 2019. Certara UK Ltd., Sheffield, UK. Available from: https:\/\/members.simcyp.com\/"},{"key":"1169_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225\u201337.","journal-title":"AAPS J"},{"key":"1169_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","volume":"23","author":"A Wilson","year":"2017","unstructured":"Wilson A, Tirona RG, Kim RB. CYP3A4 activity is markedly lower in patients with Crohn\u02bcs disease. Inflamm Bowel Dis. 2017;23:804\u201313.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bcp.12502","volume":"79","author":"N Hohmann","year":"2015","unstructured":"Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79:278\u201385.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR41","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1183\/09031936.94.07101839","volume":"7","author":"L Thorsson","year":"1994","unstructured":"Thorsson L, Edsb\u00e4cker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler\u00ae is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839\u201344.","journal-title":"Eur Respir J"},{"key":"1169_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","volume":"17","author":"S Edsb\u00e4cker","year":"2003","unstructured":"Edsb\u00e4cker S, Bengtsson B, Larsson P, Lundin P, Nilsson \u00c5, Ulmius J, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17:525\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","volume":"15","author":"P Lundin","year":"2001","unstructured":"Lundin P, Naber T, Nilsson M, Edsbacker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn\u2019s disease. Aliment Pharmacol Ther. 2001;15:45\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1365-2036.2003.01386.x","volume":"17","author":"PDP Lundin","year":"2003","unstructured":"Lundin PDP, Edsb\u00e4cker S, Bergstrand M, Ejderhamn J, Linander H, H\u00f6gberg L, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;17:85\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR45","doi-asserted-by":"crossref","unstructured":"Effinger A, O\u2019Driscoll CM, McAllister M, Fotaki N. Predicting budesonide performance in healthy subjects and patients with Crohn\u2019s disease using biorelevant in vitro dissolution testing and PBPK modeling. Eur J Pharm Sci. 2021;157:105617.","DOI":"10.1016\/j.ejps.2020.105617"},{"key":"1169_CR46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1124\/dmd.112.050732","volume":"41","author":"B Han","year":"2013","unstructured":"Han B, Mao J, Chien JY, Hall SD. Optimization of drug\u2013drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos. 2013;41:1329\u201338.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/aps.2015.122","volume":"37","author":"H-Y Wang","year":"2016","unstructured":"Wang H-Y, Chen X, Jiang J, Shi J, Hu P. Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacol Sin. 2016;37:276\u201384.","journal-title":"Acta Pharmacol Sin"},{"key":"1169_CR48","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2174\/138920012800840464","volume":"13","author":"M Chetty","year":"2012","unstructured":"Chetty M, Mattison D, Rostami-Hodjegan A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab. 2012;13:778\u201386.","journal-title":"Curr Drug Metab"},{"key":"1169_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1208\/s12248-020-00480-x","volume":"22","author":"D Liu","year":"2020","unstructured":"Liu D, Li L, Rostami-Hodjegan A, Bois FY, Jamei M. Considerations and caveats when applying global sensitivity analysis methods to physiologically based pharmacokinetic models. AAPS J. 2020;22:93.","journal-title":"AAPS J"},{"key":"1169_CR50","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","volume":"72","author":"F Sanaee","year":"2011","unstructured":"Sanaee F, Clements JD, Waugh AWG, Fedorak RN, Lewanczuk R, Jamali F. Drug\u2212disease interaction: Crohn\u2019s disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol. 2011;72:787\u201397.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF00561408","volume":"12","author":"A Melander","year":"1977","unstructured":"Melander A, Kahlmeter G, Kamme C, Ursing B. Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn\u2019s disease. Eur J Clin Pharmacol. 1977;12:69\u201372.","journal-title":"Eur J Clin Pharmacol"},{"key":"1169_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000198583","volume":"21","author":"AR Tanner","year":"1981","unstructured":"Tanner AR, Halliday JW, Powell LW. Serum prednisolone levels in Crohn\u2019s disease and coeliac disease following oral prednisolone administration. Digestion. 1981;21:310\u20135.","journal-title":"Digestion"},{"key":"1169_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF01315146","volume":"28","author":"RL Milsap","year":"1983","unstructured":"Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci. 1983;28:161\u20138.","journal-title":"Dig Dis Sci"},{"key":"1169_CR54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/j.1552-4604.1995.tb04108.x","volume":"35","author":"SS Fl\u00fcckiger","year":"1995","unstructured":"Fl\u00fcckiger SS, Schmidt C, Meyer A, Kallay Z, Johnston A, Kutz K. Pharmacokinetics of orally administered cyclosporine in patients with Crohn\u2019s disease. J Clin Pharmacol. 1995;35:681\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1169_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.1550","volume":"60","author":"A Nader","year":"2020","unstructured":"Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn\u2019s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials. J Clin Pharmacol. 2020;60:528\u201339.","journal-title":"J Clin Pharmacol"},{"key":"1169_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4240","volume":"32","author":"F Jiang","year":"2018","unstructured":"Jiang F, Peng X, Cai D, Wen D, Liu Y, Zhi M, et al. A validated LC-MS\/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: application to a pharmacokinetic assay. Biomed Chromatogr. 2018;32: e4240.","journal-title":"Biomed Chromatogr"},{"key":"1169_CR57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2036.1990.tb00496.x","volume":"4","author":"B Norlander","year":"1990","unstructured":"Norlander B, Gotthard R, Strom M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn\u2019s disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther. 1990;4:497\u2013505.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR58","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2036.1994.tb00327.x","volume":"8","author":"P Gionchetti","year":"1994","unstructured":"Gionchetti P, Campieri M, Belluzzi A, Boschi S, Brignola C, Miglioli M, et al. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers. Aliment Pharmacol Ther. 1994;8:535\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2125.1979.tb05907.x","volume":"8","author":"R Schneider","year":"1979","unstructured":"Schneider R, Bishop H, Hawkins C. Plasma propranolol concentrations and the erythrocyte sedimentation rate. Br J Clin Pharmacol. 1979;8:43\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2165\/00003088-200140100-00003","volume":"40","author":"M Schwab","year":"2001","unstructured":"Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723\u201351.","journal-title":"Clin Pharmacokinet"},{"key":"1169_CR61","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1046\/j.1365-2036.1998.00358.x","volume":"12","author":"AG Press","year":"1998","unstructured":"Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1998;12:673\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1169_CR62","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1023\/A:1018893409596","volume":"43","author":"J Fallingborg","year":"1998","unstructured":"Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn\u2019s disease. Dig Dis Sci. 1998;43:702\u20135.","journal-title":"Dig Dis Sci"},{"key":"1169_CR63","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1023\/A:1026664105112","volume":"44","author":"K Ewe","year":"1999","unstructured":"Ewe K, Schwartz S, Petersen S, Press AG. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci. 1999;44:1434\u20139.","journal-title":"Dig Dis Sci"},{"key":"1169_CR64","first-page":"114","volume":"92","author":"Y Sasaki","year":"1997","unstructured":"Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn\u2019s disease. Am J Gastroenterol. 1997;92:114\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1169_CR65","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/gut.19.8.735","volume":"19","author":"ML Lucas","year":"1978","unstructured":"Lucas ML, Cooper BT, Lei FH, Johnson IT, Holmes GK, Blair JA, et al. Acid microclimate in coeliac and Crohn\u2019s disease: a model for folate malabsorption. Gut. 1978;19:735\u201342.","journal-title":"Gut"},{"key":"1169_CR66","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1471-230X-12-175","volume":"12","author":"ACM N\u00f3brega","year":"2012","unstructured":"N\u00f3brega ACM, Ferreira BRS, Oliveira GJ, Sales KMO, Santos AA, Nobre e Souza M\u00c2, et al. Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn\u2019s disease. BMC Gastroenterol. 2012;12:175.","journal-title":"BMC Gastroenterol"},{"key":"1169_CR67","first-page":"G861","volume":"297","author":"J Keller","year":"2009","unstructured":"Keller J, Beglinger C, Holst JJ, Andresen V, Layer P. Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. Am J Physiol Liver Physiol. 2009;297:G861\u20138.","journal-title":"Am J Physiol Liver Physiol"},{"key":"1169_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00004836-199512000-00005","volume":"21","author":"V Annese","year":"1995","unstructured":"Annese V, Bassotti G, Napolitano G, Frusciante V, Bruno M, Conoscitore P, et al. Gastric emptying of solids in patients with nonobstructive Crohn\u02bcs disease is sometimes delayed. J Clin Gastroenterol. 1995;21:279\u201382.","journal-title":"J Clin Gastroenterol"},{"key":"1169_CR69","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/eci.12542","volume":"45","author":"J Keller","year":"2015","unstructured":"Keller J, Binnewies U, R\u00f6sch M, Juul Holst J, Beglinger C, Andresen V, et al. Gastric emptying and disease activity in inflammatory bowel disease. Eur J Clin Investig. 2015;45:1234\u201342.","journal-title":"Eur J Clin Investig"},{"key":"1169_CR70","first-page":"154","volume":"51","author":"AO Dami\u00e3o","year":"1996","unstructured":"Dami\u00e3o AO, Sipahi AM, Vezozzo DP, Gon\u00e7alves PL, Laudanna AA. Measurement of gastric emptying time by real-time ultrasonography in patients with Crohn\u2019s disease. Rev Hosp Clin Fac Med Sao Paulo. 1996;51:154\u20136.","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"1169_CR71","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1007\/s10620-007-9789-1","volume":"52","author":"Z Fireman","year":"2007","unstructured":"Fireman Z, Kopelman Y, Friedman S, Ephrath H, Choman E, Debby H, et al. Age and indication for referral to capsule endoscopy significantly affect small bowel transit times: the given database. Dig Dis Sci. 2007;52:2884\u20137.","journal-title":"Dig Dis Sci"},{"key":"1169_CR72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/clpt.1981.153","volume":"30","author":"S Holt","year":"1981","unstructured":"Holt S, Heading RC, Clements JA, Tothill P, Prescott LF. Acetaminophen absorption and metabolism in celiac disease and Crohn\u2019s disease. Clin Pharmacol Ther. 1981;30:232\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1169_CR73","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/MEG.0000000000000684","volume":"28","author":"E Niv","year":"2016","unstructured":"Niv E, Pinchasovich H, Yanai H. Impact of demographic and clinical parameters on video capsule transit time. Eur J Gastroenterol Hepatol. 2016;28:1161\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1169_CR74","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.crohns.2014.03.003","volume":"8","author":"E Niv","year":"2014","unstructured":"Niv E, Fishman S, Kachman H, Arnon R, Dotan I. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn\u2019s disease. J Crohns Colitis. 2014;8:1616\u201323.","journal-title":"J Crohns Colitis"},{"key":"1169_CR75","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","volume":"18","author":"M Fischer","year":"2017","unstructured":"Fischer M, Siva S, Wo JM, Fadda HM. Assessment of small intestinal transit times in ulcerative colitis and Crohn\u2019s disease patients with different disease activity using video capsule endoscopy. AAPS PharmSciTech. 2017;18:404\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"1169_CR76","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1148\/radiology.193.2.7972778","volume":"193","author":"JA van Oostayen","year":"1994","unstructured":"van Oostayen JA, Wasser MNJM, van Hogezand RA, Griffioen G, de Roos A. Activity of Crohn disease assessed by measurement of superior mesenteric artery flow with Doppler US. Radiology. 1994;193:551\u20134.","journal-title":"Radiology"},{"key":"1169_CR77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1572-0241.1998.088_c.x","volume":"93","author":"J van Oostayen","year":"1998","unstructured":"van Oostayen J. Diagnosis of Crohn\u2019s ileitis and monitoring of disease activity: value of Doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol. 1998;93:88\u201391.","journal-title":"Am J Gastroenterol"},{"key":"1169_CR78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7863\/jum.2005.24.1.59","volume":"24","author":"E Yekeler","year":"2005","unstructured":"Yekeler E, Danalioglu A, Movasseghi B, Yilmaz S, Karaca C, Kaymakoglu S, et al. Crohn disease activity evaluated by Doppler ultrasonography of the superior mesenteric artery and the affected small-bowel segments. J Ultrasound Med. 2005;24:59\u201365.","journal-title":"J Ultrasound Med"},{"key":"1169_CR79","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.crohns.2012.07.002","volume":"7","author":"P Bonnin","year":"2013","unstructured":"Bonnin P, Coelho J, Pocard M, Levy BI, Marteau P. Anti-TNF\u03b1 therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active Crohn\u2019s disease. J Crohns Colitis. 2013;7:451\u20139.","journal-title":"J Crohns Colitis"},{"key":"1169_CR80","doi-asserted-by":"publisher","first-page":"391","DOI":"10.15537\/smj.2017.4.17855","volume":"38","author":"Y Na","year":"2017","unstructured":"Na Y, Zhou J, Xiao X-M, Zhang W-X, Gao H-L, Wang Y, et al. Assessment of Crohn\u2019s disease activity by Doppler sonography. Saudi Med J. 2017;38:391\u20135.","journal-title":"Saudi Med J"},{"key":"1169_CR81","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3325\/cmj.2007.6.822","volume":"48","author":"I Sjekavica","year":"2007","unstructured":"Sjekavica I, Barbari\u0107-Babi\u0107 V, Krznari\u0107 \u017d, Molnar M, \u010cukovi\u0107-\u010cavka S, \u0160tern-Padovan R. Assessment of Crohn\u2019s disease activity by Doppler ultrasound of superior mesenteric artery and mural arteries in thickened bowel wall: cross-sectional study. Croat Med J. 2007;48:822\u201330.","journal-title":"Croat Med J"},{"key":"1169_CR82","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0009-9260(98)80153-0","volume":"53","author":"I Britton","year":"1998","unstructured":"Britton I, Maguire C, Adams C, Russell RI, Leen E. Assessment of the role and reliability of sonographic post-prandial flow response in grading Crohn\u2019s disease activity. Clin Radiol. 1998;53:599\u2013603.","journal-title":"Clin Radiol"},{"key":"1169_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/gut.43.5.645","volume":"43","author":"G Maconi","year":"1998","unstructured":"Maconi G, Parente F, Bollani S, Imbesi V, Ardizzone S, Russo A, et al. Factors affecting splanchnic haemodynamics in Crohn\u2019s disease: a prospective controlled study using Doppler ultrasound. Gut. 1998;43:645\u201350.","journal-title":"Gut"},{"key":"1169_CR84","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.crohns.2009.12.011","volume":"4","author":"S Karoui","year":"2010","unstructured":"Karoui S, Nouira K, Serghini M, Ben Mustapha N, Boubaker J, Menif E, et al. Assessment of activity of Crohn\u2019s disease by Doppler sonography of superior mesenteric artery flow. J Crohns Colitis. 2010;4:334\u201340.","journal-title":"J Crohns Colitis"},{"key":"1169_CR85","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1053\/crad.2001.0794","volume":"56","author":"MF Byrne","year":"2001","unstructured":"Byrne MF, Farrell MA, Abass S, Fitzgerald A, Varghese JC, Thornton F, et al. Assessment of Crohn\u2019s disease activity by Doppler sonography of the superior mesenteric artery, clinical evaluation and the Crohn\u2019s disease activity index: a prospective study. Clin Radiol. 2001;56:973\u20138.","journal-title":"Clin Radiol"},{"key":"1169_CR86","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ultrasmedbio.2015.08.022","volume":"42","author":"G Maconi","year":"2016","unstructured":"Maconi G, Asthana AK, Bolzacchini E, Dell\u2019Era A, Furfaro F, Bezzio C, et al. Splanchnic hemodynamics and intestinal vascularity in Crohn\u2019s disease: an in vivo evaluation using Doppler and contrast-enhanced ultrasound and biochemical parameters. Ultrasound Med Biol. 2016;42:150\u20138.","journal-title":"Ultrasound Med Biol"},{"key":"1169_CR87","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3109\/00365529609009132","volume":"31","author":"G Maconi","year":"1996","unstructured":"Maconi G, Imbesi V, Porro GB. Doppler ultrasound measurement of intestinal blood flow in inflammatory bowel disease. Scand J Gastroenterol. 1996;31:590\u20133.","journal-title":"Scand J Gastroenterol"},{"key":"1169_CR88","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0016-5085(77)80245-X","volume":"72","author":"L Hult\u00e9n","year":"1977","unstructured":"Hult\u00e9n L, Lindhagen J, Lundgren O, Fasth S, Ahr\u00e9n C. Regional intestinal blood flow in ulcerative colitis and Crohn\u2019s disease. Gastroenterology. 1977;72:388\u201396.","journal-title":"Gastroenterology"},{"key":"1169_CR89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2214\/ajr.101.2.338","volume":"101","author":"A Lunderquist","year":"1967","unstructured":"Lunderquist A, Knutsson H. Angiography in Crohn\u2019s disease of the small bowel and colon. Am J Roentgenol Radium Ther Nucl Med. 1967;101:338\u201344.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"1169_CR90","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0016-5085(19)34333-1","volume":"51","author":"MB Bacaner","year":"1966","unstructured":"Bacaner MB. Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology. 1966;51:764\u201377.","journal-title":"Gastroenterology"},{"key":"1169_CR91","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/gut.34.11.1531","volume":"34","author":"WJ Angerson","year":"1993","unstructured":"Angerson WJ, Allison MC, Baxter JN, Russell RI. Neoterminal ileal blood flow after ileocolonic resection for Crohn\u2019s disease. Gut. 1993;34:1531\u20134.","journal-title":"Gut"},{"key":"1169_CR92","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1148\/87.6.1037","volume":"87","author":"F Brahme","year":"1966","unstructured":"Brahme F. Mesenteric angiography in regional enterocolitis. Radiology. 1966;87:1037\u201342.","journal-title":"Radiology"},{"key":"1169_CR93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00054725-200207000-00003","volume":"8","author":"A Di Sabatino","year":"2002","unstructured":"Di Sabatino A, Fulle I, Ciccocioppo R, Ricevuti L, Tinozzi FP, Tinozzi S, et al. Doppler enhancement after intravenous Levovist injection in Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8:251\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0016-5107(89)72680-8","volume":"35","author":"KC Su","year":"1989","unstructured":"Su KC, Leung FW, Guth PH. Assessment of mucosal hemodynamics in normal human colon and patients with inflammatory bowel disease. Gastrointest Endosc. 1989;35:22\u20137.","journal-title":"Gastrointest Endosc"},{"key":"1169_CR95","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/bjs.1800790934","volume":"79","author":"AL Sheehan","year":"1992","unstructured":"Sheehan AL, Warren BF, Gear MWL, Shepherd NA. Fat-wrapping in Crohn\u2019s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955\u20138.","journal-title":"Br J Surg"},{"key":"1169_CR96","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/2000-1967-203","volume":"112","author":"M Th\u00f6rn","year":"2007","unstructured":"Th\u00f6rn M, Finnstr\u00f6m N, Lundgren S, Rane A, L\u00f6\u00f6f L. Expression of cytochrome P450 and MDR1 in patients with proctitis. Ups J Med Sci. 2007;112:303\u201312.","journal-title":"Ups J Med Sci"},{"key":"1169_CR97","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","volume":"210","author":"D Plewka","year":"2014","unstructured":"Plewka D, Plewka A, Szczepanik T, Morek M, Bogunia E, Wittek P, et al. Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. Pathol Res Pract. 2014;210:242\u20139.","journal-title":"Pathol Res Pract"},{"key":"1169_CR98","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1124\/dmd.114.058065","volume":"42","author":"J Jahnel","year":"2014","unstructured":"Jahnel J, Fickert P, Hauer AC, H\u00f6genauer C, Avian A, Trauner M. Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos. 2014;42:1423\u201331.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","volume":"127","author":"T Langmann","year":"2004","unstructured":"Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26\u201340.","journal-title":"Gastroenterology"},{"key":"1169_CR100","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1021\/acs.molpharmaceut.9b00459","volume":"16","author":"A Wilson","year":"2019","unstructured":"Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, et al. Crohn\u2019s disease is associated with decreased CYP3A4 and P-glycoprotein protein expression. Mol Pharm. 2019;16:4059\u201364.","journal-title":"Mol Pharm"},{"key":"1169_CR101","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1124\/dmd.120.000283","volume":"49","author":"K Takayama","year":"2021","unstructured":"Takayama K, Ito K, Matsui A, Yamashita T, Kawakami K, Hirayama D, et al. In vivo gene expression profile of human intestinal epithelial cells: from the viewpoint of drug metabolism and pharmacokinetics. Drug Metab Dispos. 2021;49:221\u201332.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR102","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0011-393X(98)85095-9","volume":"59","author":"U Klotz","year":"1998","unstructured":"Klotz U, Hoensch H, Sch\u00fctz T, Beaune P, Zanger U, Bode JC, et al. Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease. Curr Ther Res. 1998;59:556\u201363.","journal-title":"Curr Ther Res"},{"key":"1169_CR103","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ibd.20088","volume":"13","author":"H Blokzijl","year":"2007","unstructured":"Blokzijl H, Borght SV, Bok LIH, Libbrecht L, Geuken M, van den Heuvel FAJ, et al. Decreased P-glycoprotein (P-gp\/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis. 2007;13:710\u201320.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR104","doi-asserted-by":"publisher","first-page":"35630","DOI":"10.1074\/jbc.M804374200","volume":"283","author":"H Blokzijl","year":"2008","unstructured":"Blokzijl H, van Steenpaal A, Borght SV, Bok LIH, Libbrecht L, Tamminga M, et al. Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J Biol Chem. 2008;283:35630\u20137.","journal-title":"J Biol Chem"},{"key":"1169_CR105","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1124\/dmd.109.027367","volume":"37","author":"KA Wojtal","year":"2009","unstructured":"Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, et al. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos. 2009;37:1871\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR106","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1053\/j.gastro.2007.08.041","volume":"133","author":"R Thibault","year":"2007","unstructured":"Thibault R, De Coppet P, Daly K, Bourreille A, Cuff M, Bonnet C, et al. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology. 2007;133:1916\u201327.","journal-title":"Gastroenterology"},{"key":"1169_CR107","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/gut.53.1.78","volume":"53","author":"D Jung","year":"2004","unstructured":"Jung D. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004;53:78\u201384.","journal-title":"Gut"},{"key":"1169_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.crohns.2011.08.003","volume":"6","author":"M Girardin","year":"2012","unstructured":"Girardin M, Dionne S, Goyette P, Rioux J, Bitton A, Elimrani I, et al. Expression and functional analysis of intestinal organic cation\/l-carnitine transporter (OCTN) in Crohn\u2019s disease. J Crohns Colitis. 2012;6:189\u201397.","journal-title":"J Crohns Colitis"},{"key":"1169_CR109","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s10620-005-3053-3","volume":"50","author":"AL Buchman","year":"2005","unstructured":"Buchman AL, Paine MF, Wallin A, Ludington SS. A higher dose requirement of tacrolimus in active Crohn\u2019s disease may be related to a high intestinal P-glycoprotein content. Dig Dis Sci. 2005;50:2312\u20135.","journal-title":"Dig Dis Sci"},{"key":"1169_CR110","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease\u2013drug\u2013drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735\u201340.","journal-title":"Clin Pharmacol Ther"},{"key":"1169_CR111","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","volume":"8","author":"RF Frye","year":"2002","unstructured":"Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-\u03b1 and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002;8:315\u20139.","journal-title":"J Card Fail"},{"key":"1169_CR112","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","volume":"87","author":"LP Rivory","year":"2002","unstructured":"Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87:277\u201380.","journal-title":"Br J Cancer"},{"key":"1169_CR113","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.32.3.359","volume":"32","author":"JA Sunman","year":"2004","unstructured":"Sunman JA, Hawke RL, LeCluyse EL, Kashuba ADM. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004;32:359\u201363.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR114","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35:1687\u201393.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR115","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1124\/dmd.111.038679","volume":"39","author":"LJ Dickmann","year":"2011","unstructured":"Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39:1415\u201322.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR116","doi-asserted-by":"crossref","unstructured":"Korolkova OY, Myers JN, Pellom ST, Wang L, M\u2019koma AE. Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn\u2019s colitides. Clin Med Insights Gastroenterol. 2015;8:CGast.S20612.","DOI":"10.4137\/CGast.S20612"},{"key":"1169_CR117","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12223-011-0051-z","volume":"56","author":"L Gombo\u0161ov\u00e1","year":"2011","unstructured":"Gombo\u0161ov\u00e1 L, Laz\u00farov\u00e1 I, Zakuciov\u00e1 M, \u010curov\u00e1 K, Kme\u0165ov\u00e1 M, Petr\u00e1\u0161ov\u00e1 D, et al. Genes of intestinal Escherichia coli and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn\u2019s disease. Folia Microbiol (Praha). 2011;56:367\u201372.","journal-title":"Folia Microbiol (Praha)"},{"key":"1169_CR118","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/cts.13164","volume":"15","author":"L Wang","year":"2022","unstructured":"Wang L, Chen Y, Zhou W, Miao X, Zhou H. Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases. Clin Transl Sci. 2022;15:464\u201376.","journal-title":"Clin Transl Sci"},{"key":"1169_CR119","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00870992","volume":"31","author":"A Baruzzi","year":"1986","unstructured":"Baruzzi A, Contin M, Perucca E, Albani F, Riva R. Altered serum protein binding of carbamazepine in disease states associated with an increased? 1-acid glycoprotein concentration. Eur J Clin Pharmacol. 1986;31:85\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1169_CR120","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/gut.12.4.297","volume":"12","author":"B Weeke","year":"1971","unstructured":"Weeke B, Jarnum S. Serum concentration of 19 serum proteins in Crohn\u2019s disease and ulcerative colitis. Gut. 1971;12:297\u2013302.","journal-title":"Gut"},{"key":"1169_CR121","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024925","volume":"100","author":"F-S Zhou","year":"2021","unstructured":"Zhou F-S, Gao N, Sun X, Jiang X-Y, Chen J-J, Mao Q-Q, et al. C-reactive protein\/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease. Medicine (Baltim). 2021;100: e24925.","journal-title":"Medicine (Baltim)"},{"key":"1169_CR122","first-page":"119","volume":"58","author":"K Szczeklik","year":"2018","unstructured":"Szczeklik K, Krzy\u015bciak W, Cibor D, Kozio\u0142 K, Pocztar H, Pytko-Polo\u0144czyk J, et al. Evaluation of plasma concentrations of selected antioxidant parameters in patients with active Crohn\u2019s disease. Folia Med Crac. 2018;58:119\u201330.","journal-title":"Folia Med Crac"},{"key":"1169_CR123","doi-asserted-by":"crossref","unstructured":"Saadoun MM, Nosair NA el-A, Abdel-Azeez HA-H, Sharaf SM, Ahmed MH. Serum visfatin as a diagnostic marker of active inflammatory bowel disease. J Gastrointest Liver Dis. 2021;30:339\u201345.","DOI":"10.15403\/jgld-3504"},{"key":"1169_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/690853","volume":"2014","author":"A Sahin","year":"2014","unstructured":"Sahin A, Calhan T, Cengiz M, Kahraman R, Aydin K, Ozdil K, et al. Serum interleukin 17 levels in patients with Crohn\u2019s disease: real life data. Dis Markers. 2014;2014:1\u20136.","journal-title":"Dis Markers"},{"key":"1169_CR125","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.crohns.2010.07.010","volume":"4","author":"J Nagy","year":"2010","unstructured":"Nagy J, Lakner L, Po\u00f3r VS, Pandur E, M\u00f3zsik G, Miseta A, et al. Serum prohepcidin levels in chronic inflammatory bowel diseases. J Crohns Colitis. 2010;4:649\u201353.","journal-title":"J Crohns Colitis"},{"key":"1169_CR126","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/bcp.13641","volume":"84","author":"C Li","year":"2018","unstructured":"Li C, Shoji S, Beebe J. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol. 2018;84:2059\u201374.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR127","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3164\/jcbn.14-77","volume":"55","author":"J Iwamoto","year":"2014","unstructured":"Iwamoto J, Honda A, Miyamoto Y, Miyazaki T, Murakami M, Saito Y, et al. Serum carnitine as an independent biomarker of malnutrition in patients with impaired oral intake. J Clin Biochem Nutr. 2014;55:221\u20137.","journal-title":"J Clin Biochem Nutr"},{"key":"1169_CR128","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejim.2010.04.012","volume":"21","author":"DD Mija\u010d","year":"2010","unstructured":"Mija\u010d DD, Jankovi\u0107 GLJ, Jorga J, Krsti\u0107 MN. Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med. 2010;21:315\u20139.","journal-title":"Eur J Intern Med"},{"key":"1169_CR129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF01347889","volume":"30","author":"U Karbach","year":"1985","unstructured":"Karbach U, Ewe K, Dehos H. Antiinflammatory treatment and intestinal? 1-antitrypsin clearance in active Crohn\u2019s disease. Dig Dis Sci. 1985;30:229\u201335.","journal-title":"Dig Dis Sci"},{"key":"1169_CR130","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1440-1746.1994.tb01557.x","volume":"9","author":"\u00d6 Ahrenstedt","year":"1994","unstructured":"Ahrenstedt \u00d6, H\u00e4llgren R, Knutson L. Jejunal release of prostaglandin E 2 in Crohn\u2019s disease: relation to disease activity and first-degree relatives. J Gastroenterol Hepatol. 1994;9:539\u201343.","journal-title":"J Gastroenterol Hepatol"},{"key":"1169_CR131","doi-asserted-by":"crossref","unstructured":"Cibor D, Szczeklik K, Brzozowski B, Mach T, Owczarek D. Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease. J Physiol Pharmacol. 2019;70:95\u2013104.","DOI":"10.1093\/ecco-jcc\/jjy222.146"},{"key":"1169_CR132","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1470320314521086","volume":"16","author":"M Garg","year":"2015","unstructured":"Garg M, Burrell LM, Velkoska E, Griggs K, Angus PW, Gibson PR, et al. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study. J Renin Angiotensin Aldosterone Syst. 2015;16:559\u201369.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1169_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MIB.0000000000000508","volume":"21","author":"T Engel","year":"2015","unstructured":"Engel T, Ben-Horin S, Beer-Gabel M. Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn\u02bcs disease. Inflamm Bowel Dis. 2015;21:1.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR134","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/BF02774974","volume":"27","author":"R Baba","year":"1992","unstructured":"Baba R, Yashiro K, Nagasako K, Obata H. Significance of serum sialic acid in patients with Crohn\u2019s disease. Gastroenterol Jpn. 1992;27:604\u201310.","journal-title":"Gastroenterol Jpn"},{"key":"1169_CR135","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/00365520601010115","volume":"42","author":"M Eivindson","year":"2007","unstructured":"Eivindson M, Gr\u00f8nb\u00e6k H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, et al. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn\u2019s disease. Scand J Gastroenterol. 2007;42:464\u201370.","journal-title":"Scand J Gastroenterol"},{"key":"1169_CR136","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015664","volume":"98","author":"Q Su","year":"2019","unstructured":"Su Q, Li X, Mo W, Yang Z. Low serum bilirubin, albumin, and uric acid levels in patients with Crohn\u2019s disease. Medicine (Baltim). 2019;98: e15664.","journal-title":"Medicine (Baltim)"},{"key":"1169_CR137","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.12659\/MSM.897460","volume":"22","author":"G Qin","year":"2016","unstructured":"Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, et al. Serum albumin and C-reactive protein\/albumin ratio are useful biomarkers of Crohn\u2019s disease activity. Med Sci Monit. 2016;22:4393\u2013400.","journal-title":"Med Sci Monit"},{"key":"1169_CR138","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/jgh.13254","volume":"31","author":"M Kaplan","year":"2016","unstructured":"Kaplan M, Yuksel M, Ates I, Kilic ZMY, Kilic H, Kuzu UB, et al. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases? J Gastroenterol Hepatol. 2016;31:1120\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"1169_CR139","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fphys.2019.00499","volume":"10","author":"AR Bourgonje","year":"2019","unstructured":"Bourgonje AR, von Martels JZH, Bulthuis MLC, van Londen M, Faber KN, Dijkstra G, et al. Crohn\u2019s disease in clinical remission is marked by systemic oxidative stress. Front Physiol. 2019;10:499.","journal-title":"Front Physiol"},{"key":"1169_CR140","first-page":"598","volume":"130","author":"D Cibor","year":"2020","unstructured":"Cibor D, Szczeklik K, Kozio\u0142 K, Pocztar H, Mach T, Owczarek D. Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with varying activities of inflammatory bowel disease. Pol Arch Intern Med. 2020;130:598\u2013606.","journal-title":"Pol Arch Intern Med"},{"key":"1169_CR141","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ibd.20383","volume":"14","author":"M Krzystek-Korpacka","year":"2008","unstructured":"Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14:794\u2013802.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR142","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.dld.2005.01.010","volume":"37","author":"J-M Reimund","year":"2005","unstructured":"Reimund J-M, Arondel Y, Escalin G, Finck G, Baumann R, Duclos B. Immune activation and nutritional status in adult Crohn\u2019s disease patients. Dig Liver Dis. 2005;37:424\u201331.","journal-title":"Dig Liver Dis"},{"key":"1169_CR143","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0016-5085(75)80129-6","volume":"68","author":"S Jarnum","year":"1975","unstructured":"Jarnum S, Jensen KB. Fecal radioiodide excretion following intravenous injection of 131I-albumin and 125I-immunoglobulin G in chronic inflammatory bowel disease. Gastroenterology. 1975;68:1433\u201344.","journal-title":"Gastroenterology"},{"key":"1169_CR144","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1097\/MIB.0000000000000475","volume":"21","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn\u02bcs disease. Inflamm Bowel Dis. 2015;21:2114\u201322.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR145","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0148607107031004311","volume":"31","author":"K Vagianos","year":"2007","unstructured":"Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. J Parenter Enter Nutr. 2007;31:311\u20139.","journal-title":"J Parenter Enter Nutr"},{"key":"1169_CR146","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/gastro\/gox002","volume":"5","author":"X Liu","year":"2017","unstructured":"Liu X, Wu X, Zhou C, Hu T, Ke J, Chen Y, et al. Preoperative hypoalbuminemia is associated with an increased risk for intra-abdominal septic complications after primary anastomosis for Crohn\u2019s disease. Gastroenterol Rep. 2017;5:298\u2013304.","journal-title":"Gastroenterol Rep"},{"key":"1169_CR147","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/ecco-jcc\/jjz083","volume":"13","author":"GC Nguyen","year":"2019","unstructured":"Nguyen GC, Du L, Chong RY, Jackson TD. Hypoalbuminaemia and postoperative outcomes in inflammatory bowel disease: the NSQIP surgical cohort. J Crohns Colitis. 2019;13:1433\u20138.","journal-title":"J Crohns Colitis"},{"key":"1169_CR148","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0753-3322(96)82632-1","volume":"49","author":"G Ricci","year":"1995","unstructured":"Ricci G, Ambrosi A, Resca D, Masotti M, Alvisi V. Comparison of serum total sialic acid, C-reactive protein, \u03b11-acid glycoprotein and \u03b22-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother. 1995;49:259\u201362.","journal-title":"Biomed Pharmacother"},{"key":"1169_CR149","doi-asserted-by":"crossref","unstructured":"Gesink-van der Veer BJ, Burm AG, Hennis PJ, Bovill JG. Alfentanil requirement in Crohn\u2019s disease. Increased alfentanil dose requirement in patients with Crohn\u2019s disease. Anaesthesia. 1989;44:209\u201311.","DOI":"10.1111\/j.1365-2044.1989.tb11224.x"},{"key":"1169_CR150","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/jcp.15.6.585","volume":"15","author":"JA Easton","year":"1962","unstructured":"Easton JA, Hardwicke J, Whitehead PH. The estimation of two alpha1 glycoproteins (orosomucoid and another alpha1 acid glycoprotein) in health and disease. J Clin Pathol. 1962;15:585\u201390.","journal-title":"J Clin Pathol"},{"key":"1169_CR151","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/jcp.52.1.47","volume":"52","author":"CJ Darroch","year":"1999","unstructured":"Darroch CJ, Barnes RMR, Dawson J. Circulating antibodies to Saccharomyces cerevisiae (bakers\u2019\/brewers\u2019 yeast) in gastrointestinal disease. J Clin Pathol. 1999;52:47\u201353.","journal-title":"J Clin Pathol"},{"key":"1169_CR152","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13244-012-0154-3","volume":"3","author":"N Griffin","year":"2012","unstructured":"Griffin N, Grant LA, Anderson S, Irving P, Sanderson J. Small bowel MR enterography: problem solving in Crohn\u2019s disease. Insights Imaging. 2012;3:251\u201363.","journal-title":"Insights Imaging"},{"key":"1169_CR153","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","volume":"17","author":"PS Dulai","year":"2019","unstructured":"Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, et al. Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019;17:2634\u201343.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1169_CR154","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/2050640616635957","volume":"4","author":"M Scharl","year":"2016","unstructured":"Scharl M, Bruckner RS, Rogler G. The two sides of the coin: similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United Eur Gastroenterol J. 2016;4:506\u201314.","journal-title":"United Eur Gastroenterol J"},{"key":"1169_CR155","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0002-8223(21)08378-4","volume":"84","author":"P Hodges","year":"1984","unstructured":"Hodges P, Gee M, Grace M, Sherbaniuk RW, Wensel RH, Thomson ABR. Protein-energy intake and malnutrition in Crohn\u2019s disease. J Am Diet Assoc. 1984;84:1460\u20134.","journal-title":"J Am Diet Assoc"},{"key":"1169_CR156","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0720-048X(00)00240-0","volume":"35","author":"Z Tarj\u00e1n","year":"2000","unstructured":"Tarj\u00e1n Z, T\u00f3th G, Gy\u00f6rke T, Mester \u00c1, Karlinger K, Mak\u00f3 EK. Ultrasound in Crohn\u2019s disease of the small bowel. Eur J Radiol. 2000;35:176\u201382.","journal-title":"Eur J Radiol"},{"key":"1169_CR157","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1111\/j.1572-0241.1999.01442.x","volume":"94","author":"D Ludwig","year":"1999","unstructured":"Ludwig D, Wiener S, Br\u00fcning A, Schwarting K, Jantschek G, Stange EF. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn\u2019s disease: a prospective follow-up study. Am J Gastroenterol. 1999;94:2942\u201350.","journal-title":"Am J Gastroenterol"},{"key":"1169_CR158","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2214\/AJR.08.1267","volume":"192","author":"ME Baker","year":"2009","unstructured":"Baker ME, Walter J, Obuchowski NA, Achkar J-P, Einstein D, Veniero JC, et al. Mural attenuation in normal small bowel and active inflammatory Crohn\u2019s disease on CT enterography: location, absolute attenuation, relative attenuation, and the effect of wall thickness. Am J Roentgenol. 2009;192:417\u201323.","journal-title":"Am J Roentgenol"},{"key":"1169_CR159","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/cts.12938","volume":"14","author":"CA Vyhlidal","year":"2021","unstructured":"Vyhlidal CA, Chapron BD, Ahmed A, Singh V, Casini R, Shakhnovich V. Effect of Crohn\u2019s disease on villous length and CYP3A4 expression in the pediatric small intestine. Clin Transl Sci. 2021;14:729\u201336.","journal-title":"Clin Transl Sci"},{"key":"1169_CR160","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/gutjnl-2011-301364","volume":"62","author":"C G\u00fcnther","year":"2013","unstructured":"G\u00fcnther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. 2013;62:1062\u201371.","journal-title":"Gut"},{"key":"1169_CR161","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10350-004-0831-5","volume":"48","author":"F Sipos","year":"2005","unstructured":"Sipos F, Moln\u00e1r B, Z\u00e1goni T, Berczi L, Tulassay Z. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum. 2005;48:775\u201386.","journal-title":"Dis Colon Rectum"},{"key":"1169_CR162","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00535-004-1335-8","volume":"39","author":"AP Zbar","year":"2004","unstructured":"Zbar AP, Simopoulos C, Karayiannakis AJ. Cadherins: an integral role in inflammatory bowel disease and mucosal restitution. J Gastroenterol. 2004;39:413\u201321.","journal-title":"J Gastroenterol"},{"key":"1169_CR163","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/his.12222","volume":"63","author":"G Liapis","year":"2013","unstructured":"Liapis G, Boletis J, Skalioti C, Bamias G, Tsimaratou K, Patsouris E, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology. 2013;63:649\u201358.","journal-title":"Histopathology"},{"key":"1169_CR164","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00384-009-0756-5","volume":"24","author":"L M\u00e4kitalo","year":"2009","unstructured":"M\u00e4kitalo L, Sipponen T, K\u00e4rkk\u00e4inen P, Kolho K-L, Saarialho-Kere U. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn\u2019s disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis. 2009;24:1157\u201367.","journal-title":"Int J Colorectal Dis"},{"key":"1169_CR165","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3109\/00365528609003110","volume":"21","author":"L Tougaard","year":"1986","unstructured":"Tougaard L, Giese B, Pedersen BH, Binder V. Bile acid metabolism in patients with Crohn\u2019s disease in terminal ileum. Scand J Gastroenterol. 1986;21:627\u201333.","journal-title":"Scand J Gastroenterol"},{"key":"1169_CR166","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1086\/510385","volume":"44","author":"PB Eckburg","year":"2007","unstructured":"Eckburg PB, Relman DA. The role of microbes in Crohn\u2019s disease. Clin Infect Dis. 2007;44:256\u201362.","journal-title":"Clin Infect Dis"},{"key":"1169_CR167","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. 2007;104:13780\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"1169_CR168","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","volume":"152","author":"RB Sartor","year":"2017","unstructured":"Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152:327-339.e4.","journal-title":"Gastroenterology"},{"key":"1169_CR169","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1124\/dmd.115.065714","volume":"43","author":"HI Swanson","year":"2015","unstructured":"Swanson HI. Drug metabolism by the host and gut microbiota: a partnership or rivalry? Drug Metab Dispos. 2015;43:1499\u2013504.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR170","first-page":"375","volume":"89","author":"EF Enright","year":"2016","unstructured":"Enright EF, Gahan CGM, Joyce SA, Griffin BT. The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J Biol Med. 2016;89:375\u201382.","journal-title":"Yale J Biol Med"},{"key":"1169_CR171","first-page":"124","volume":"32","author":"A Mertz","year":"2019","unstructured":"Mertz A. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019;32:124\u201333.","journal-title":"Ann Gastroenterol"},{"key":"1169_CR172","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/pmic.201500386","volume":"16","author":"A Cie\u015blak","year":"2016","unstructured":"Cie\u015blak A, Kelly I, Trottier J, Verreault M, Wunsch E, Milkiewicz P, et al. Selective and sensitive quantification of the cytochrome P450 3A4 protein in human liver homogenates through multiple reaction monitoring mass spectrometry. Proteomics. 2016;16:2827\u201337. https:\/\/doi.org\/10.1002\/pmic.201500386.","journal-title":"Proteomics"},{"key":"1169_CR173","doi-asserted-by":"publisher","first-page":"39573","DOI":"10.1038\/srep39573","volume":"6","author":"M Milkiewicz","year":"2016","unstructured":"Milkiewicz M, Klak M, Kempinska-Podhorodecka A, Wiechowska-Kozlowska A, Urasinska E, Blatkiewicz M, et al. Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis. Sci Rep. 2016;6:39573.","journal-title":"Sci Rep"},{"key":"1169_CR174","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1021\/acs.molpharmaceut.8b00941","volume":"16","author":"N Couto","year":"2019","unstructured":"Couto N, Al-Majdoub ZM, Achour B, Wright PC, Rostami-Hodjegan A, Barber J. Quantification of proteins involved in drug metabolism and disposition in the human liver using label-free global proteomics. Mol Pharm. 2019;16:632\u201347.","journal-title":"Mol Pharm"},{"key":"1169_CR175","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1124\/dmd.116.070763","volume":"44","author":"MA Cerny","year":"2016","unstructured":"Cerny MA. Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006\u20132015. Drug Metab Dispos. 2016;44:1246\u201352.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR176","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1743-3150.2004.00487.x","volume":"16","author":"E Ekblad","year":"2004","unstructured":"Ekblad E, Bauer AJ. Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity. Neurogastroenterol Motil. 2004;16:123\u20138.","journal-title":"Neurogastroenterol Motil"},{"key":"1169_CR177","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/01.MIB.0000171872.70738.58","volume":"11","author":"C Abad","year":"2005","unstructured":"Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garc\u00eda-G\u00f3mez M, et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis. 2005;11:674\u201384.","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR178","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13198","volume":"30","author":"F Soufflet","year":"2018","unstructured":"Soufflet F, Biraud M, Rolli-Derkinderen M, Lardeux B, Trang C, Coron E, et al. Modulation of VIPergic phenotype of enteric neurons by colonic biopsy supernatants from patients with inflammatory bowel diseases: involvement of IL-6 in Crohn\u2019s disease. Neurogastroenterol Motil. 2018;30: e13198.","journal-title":"Neurogastroenterol Motil"},{"key":"1169_CR179","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2009.05.051","volume":"138","author":"P Picotti","year":"2009","unstructured":"Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell. 2009;138:795\u2013806.","journal-title":"Cell"},{"key":"1169_CR180","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1002\/jps.22612","volume":"100","author":"S Ohtsuki","year":"2011","unstructured":"Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci. 2011;100:3547\u201359.","journal-title":"J Pharm Sci"},{"key":"1169_CR181","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/bdd.1810","volume":"34","author":"MD Harwood","year":"2013","unstructured":"Harwood MD, Neuhoff S, Carlson GL, Warhurst G, Rostami-Hodjegan A. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos. 2013;34:2\u201328.","journal-title":"Biopharm Drug Dispos"},{"key":"1169_CR182","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cpt.1301","volume":"105","author":"M Drozdzik","year":"2019","unstructured":"Drozdzik M, Busch D, Lapczuk J, M\u00fcller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2019;105:1204\u201312.","journal-title":"Clin Pharmacol Ther"},{"key":"1169_CR183","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1023\/A:1026183200740","volume":"20","author":"S Mouly","year":"2003","unstructured":"Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003;20:1595\u20139.","journal-title":"Pharm Res"},{"key":"1169_CR184","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1021\/mp100015x","volume":"7","author":"A Bruy\u00e8re","year":"2010","unstructured":"Bruy\u00e8re A, Decl\u00e8ves X, Bouzom F, Ball K, Marques C, Treton X, et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm. 2010;7:1596\u2013607.","journal-title":"Mol Pharm"},{"key":"1169_CR185","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","volume":"60","author":"M Thorn","year":"2005","unstructured":"Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005;60:54\u201360.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR186","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1124\/dmd.30.1.4","volume":"30","author":"T Nakamura","year":"2002","unstructured":"Nakamura T, Sakaeda T, Ohmoto N, Tamura T, Aoyama N, Shirakawa T, et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos. 2002;30:4\u20136.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR187","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/dmd.104.001354","volume":"33","author":"C Zimmermann","year":"2005","unstructured":"Zimmermann C, Gutmann H, Hruz P, Gutzwiller J-P, Beglinger C, Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos. 2005;33:219\u201324.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR188","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","volume":"29","author":"G Englund","year":"2006","unstructured":"Englund G, Rorsman F, R\u00f6nnblom A, Karlbom U, Lazorova L, Gr\u00e5sj\u00f6 J, et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006;29:269\u201377.","journal-title":"Eur J Pharm Sci"},{"key":"1169_CR189","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejps.2006.03.003","volume":"28","author":"A Seithel","year":"2006","unstructured":"Seithel A, Karlsson J, Hilgendorf C, Bj\u00f6rquist A, Ungell A-L. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci. 2006;28:291\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"1169_CR190","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1124\/dmd.107.014902","volume":"35","author":"C Hilgendorf","year":"2007","unstructured":"Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell A-L, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35:1333\u201340.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR191","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227\u201332.","journal-title":"Nat Rev Genet"},{"key":"1169_CR192","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bmj.2.6039.794","volume":"2","author":"RE Schneider","year":"1976","unstructured":"Schneider RE, Babb J, Bishop H, Mitchard M, Hoare AM. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn\u2019s disease. BMJ. 1976;2:794\u20135.","journal-title":"BMJ"},{"key":"1169_CR193","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. J Parenter Enter Nutr. 2019;43:181\u201393.","journal-title":"J Parenter Enter Nutr"},{"key":"1169_CR194","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/gut.27.Suppl_1.67","volume":"27","author":"J Powell-Tuck","year":"1986","unstructured":"Powell-Tuck J. Protein metabolism in inflammatory bowel disease. Gut. 1986;27:67\u201371.","journal-title":"Gut"},{"key":"1169_CR195","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bdd.1996","volume":"37","author":"M Ye","year":"2016","unstructured":"Ye M, Nagar S, Korzekwa K. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding. Biopharm Drug Dispos. 2016;37:123\u201341.","journal-title":"Biopharm Drug Dispos"},{"key":"1169_CR196","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"GR Wilkinson","year":"1975","unstructured":"Wilkinson GR, Shand DG. Commentary: a physio-logical approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1169_CR197","first-page":"1350","volume":"27","author":"RS Obach","year":"1999","unstructured":"Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1169_CR198","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/00498250701658296","volume":"37","author":"M Baker","year":"2007","unstructured":"Baker M, Parton T. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica. 2007;37:1110\u201334.","journal-title":"Xenobiotica"},{"key":"1169_CR199","first-page":"659","volume":"38","author":"B Takac","year":"2014","unstructured":"Takac B, Mihaljevi\u0107 S, Stefani\u0107 M, Glavas-Obrovac L, Kibel A, Samardzija M. Importance of interleukin 6 in pathogenesis of inflammatory bowel disease. Coll Antropol. 2014;38:659\u201364.","journal-title":"Coll Antropol"},{"key":"1169_CR200","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11894-016-0511-3","volume":"18","author":"RE Carroll","year":"2016","unstructured":"Carroll RE, Benedetti E, Schowalter JP, Buchman AL. Management and complications of short bowel syndrome: an updated review. Curr Gastroenterol Rep. 2016;18:40.","journal-title":"Curr Gastroenterol Rep"},{"key":"1169_CR201","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.clnu.2016.09.028","volume":"36","author":"S Boccia","year":"2017","unstructured":"Boccia S, Torre I, Santarpia L, Iervolino C, Del Piano C, Puggina A, et al. Intestinal microbiota in adult patients with Short Bowel Syndrome: preliminary results from a pilot study. Clin Nutr. 2017;36:1707\u20139.","journal-title":"Clin Nutr"},{"key":"1169_CR202","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ajcn\/75.5.922","volume":"75","author":"TR Ziegler","year":"2002","unstructured":"Ziegler TR, Fern\u00e1ndez-Est\u00edvariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM, et al. Distribution of the H+\/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr. 2002;75:922\u201330.","journal-title":"Am J Clin Nutr"},{"key":"1169_CR203","first-page":"G116","volume":"297","author":"F Joly","year":"2009","unstructured":"Joly F, Mayeur C, Messing B, Lavergne-Slove A, Cazals-Hatem D, Noordine M-L, et al. Morphological adaptation with preserved proliferation\/transporter content in the colon of patients with short bowel syndrome. Am J Physiol Liver Physiol. 2009;297:G116\u201323.","journal-title":"Am J Physiol Liver Physiol"},{"key":"1169_CR204","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/0148607107031003240","volume":"31","author":"C Compher","year":"2007","unstructured":"Compher C, Rubesin S, Kinosian B, Madaras J, Metz D. Noninvasive measurement of transit time in short bowel syndrome. J Parenter Enter Nutr. 2007;31:240\u20135.","journal-title":"J Parenter Enter Nutr"},{"key":"1169_CR205","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/gut.27.1.66","volume":"27","author":"WJF Fitzpatrick","year":"1986","unstructured":"Fitzpatrick WJF, Zentler-Munro PL, Northfield TC. Ileal resection: effect of cimetidine and taurine on intrajejunal bile acid precipitation and lipid solubilisation. Gut. 1986;27:66\u201372.","journal-title":"Gut"},{"key":"1169_CR206","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1172\/JCI105823","volume":"47","author":"BW Van Deest","year":"1968","unstructured":"Van Deest BW, Fordtran JS, Morawski SG, Wilson JD. Bile salt and micellar fat concentration in proximal small bowel contents of ileectomy patients. J Clin Investig. 1968;47:1314\u201324.","journal-title":"J Clin Investig"},{"key":"1169_CR207","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1177\/0148607114525210","volume":"38","author":"KA Tappenden","year":"2014","unstructured":"Tappenden KA. Intestinal adaptation following resection. J Parenter Enter Nutr. 2014;38:23S-31S.","journal-title":"J Parenter Enter Nutr"},{"key":"1169_CR208","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2165\/00003088-200443140-00001","volume":"43","author":"R Severijnen","year":"2004","unstructured":"Severijnen R, Bayat N, Bakker H, Tolboom J, Bongaerts G. Enteral drug absorption in patients with short small bowel a review. Clin Pharmacokinet. 2004;43:951\u201362.","journal-title":"Clin Pharmacokinet"},{"key":"1169_CR209","doi-asserted-by":"publisher","first-page":"38S","DOI":"10.1177\/0148607113520618","volume":"38","author":"VJ Kumpf","year":"2014","unstructured":"Kumpf VJ. Pharmacologic management of diarrhea in patients with short bowel syndrome. J Parenter Enter Nutr. 2014;38:38S-44S.","journal-title":"J Parenter Enter Nutr"},{"key":"1169_CR210","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0016-5085(72)80109-4","volume":"62","author":"AF Hofmann","year":"1972","unstructured":"Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. Gastroenterology. 1972;62:918\u201334.","journal-title":"Gastroenterology"},{"key":"1169_CR211","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1172\/JCI107720","volume":"53","author":"E Krag","year":"1974","unstructured":"Krag E, Phillips SF. Active and passive bile acid absorption in man. Perfusion studies of the ileum and jejunum. J Clin Investig. 1974;53:1686\u201394.","journal-title":"J Clin Investig"},{"key":"1169_CR212","first-page":"21","volume":"10","author":"AL Ticho","year":"2020","unstructured":"Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. Intestinal absorption of bile acids in health and disease. Compr Physiol. 2020;10:21\u201356.","journal-title":"Compr Physiol"},{"key":"1169_CR213","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","volume":"24","author":"WA Alrefai","year":"2007","unstructured":"Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24:1803\u201323.","journal-title":"Pharm Res"},{"key":"1169_CR214","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.1988.tb03348.x","volume":"25","author":"M Mehta","year":"1988","unstructured":"Mehta M, Venkataramanan R, Burckart G, Ptachcinski R, Delamos B, Stachak S, et al. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol. 1988;25:579\u201384.","journal-title":"Br J Clin Pharmacol"},{"key":"1169_CR215","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10717544.2010.512024","volume":"18","author":"K Kim","year":"2011","unstructured":"Kim K, Yoon I, Chun I, Lee N, Kim T, Gwak HS. Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats. Drug Deliv. 2011;18:79\u201383.","journal-title":"Drug Deliv"},{"key":"1169_CR216","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/21553769.2013.879925","volume":"7","author":"M Stojan\u010devi\u0107","year":"2013","unstructured":"Stojan\u010devi\u0107 M, Pavlovi\u0107 N, Golo\u010dorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. Front Life Sci. 2013;7:112\u201322.","journal-title":"Front Life Sci"},{"key":"1169_CR217","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4140\/TCP.n.2006.262","volume":"21","author":"GR Zanni","year":"2006","unstructured":"Zanni GR, Wick JY. Ostomy care and the consultant pharmacist. Consult Pharm. 2006;21:262\u201374.","journal-title":"Consult Pharm"},{"key":"1169_CR218","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1208\/s12248-017-0099-z","volume":"19","author":"RH Rose","year":"2017","unstructured":"Rose RH, Turner DB, Neuhoff S, Jamei M. Incorporation of the time-varying postprandial increase in splanchnic blood flow into a PBPK model to predict the effect of food on the pharmacokinetics of orally administered high-extraction drugs. AAPS J. 2017;19:1205\u201317.","journal-title":"AAPS J"},{"key":"1169_CR219","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0169-409X(97)00041-0","volume":"27","author":"P Watkins","year":"1997","unstructured":"Watkins P. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997;27:161\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"1169_CR220","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0168-3659(95)00147-6","volume":"39","author":"LZ Benet","year":"1996","unstructured":"Benet LZ, Wu C-Y, Hebert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release. 1996;39:139\u201343.","journal-title":"J Control Release"},{"key":"1169_CR221","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1021\/mp900253n","volume":"6","author":"LZ Benet","year":"2009","unstructured":"Benet LZ. The drug transporter\u2212metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6:1631\u201343.","journal-title":"Mol Pharm"},{"key":"1169_CR222","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2174\/138920010794328913","volume":"11","author":"AS Darwich","year":"2010","unstructured":"Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the \u201cAdvanced Dissolution, Absorption, Metabolism (ADAM)\u201d model. Curr Drug Metab. 2010;11:716\u201329.","journal-title":"Curr Drug Metab"},{"key":"1169_CR223","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/jps.21572","volume":"98","author":"R Badhan","year":"2009","unstructured":"Badhan R, Penny J, Galetin A, Houston JB. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci. 2009;98:2180\u201397.","journal-title":"J Pharm Sci"},{"key":"1169_CR224","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1018872207437","volume":"16","author":"K Ito","year":"1999","unstructured":"Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption\u2013theoretical approach. Pharm Res. 1999;16:225\u201331.","journal-title":"Pharm Res"},{"key":"1169_CR225","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/jps.23623","volume":"102","author":"T Watanabe","year":"2013","unstructured":"Watanabe T, Maeda K, Nakai C, Sugiyama Y. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study. J Pharm Sci. 2013;102:3196\u2013204.","journal-title":"J Pharm Sci"},{"key":"1169_CR226","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1124\/jpet.300.3.1036","volume":"300","author":"CL Cummins","year":"2002","unstructured":"Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300:1036\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"1169_CR227","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1124\/jpet.103.058065","volume":"308","author":"CL Cummins","year":"2004","unstructured":"Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-Transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308:143\u201355.","journal-title":"J Pharmacol Exp Ther"},{"key":"1169_CR228","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","volume":"14","author":"G Rogler","year":"2020","unstructured":"Rogler G. Efficacy of JAK inhibitors in Crohn\u2019s disease. J Crohns Colitis. 2020;14:S746\u201354.","journal-title":"J Crohns Colitis"},{"key":"1169_CR229","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","volume":"19","author":"B Verstockt","year":"2022","unstructured":"Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, et al. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2022;19:351\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1169_CR230","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fphar.2021.651415","volume":"12","author":"B Al-Bawardy","year":"2021","unstructured":"Al-Bawardy B, Shivashankar R, Proctor DD. Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol. 2021;12:569.","journal-title":"Front Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01169-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T04:56:21Z","timestamp":1727931381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":230,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01169-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"3 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PBPK models were provided by Certara. Amin Rostami-Hodjegan is an employee of Certara UK Limited and holds shares in Certara. The rest of the authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was supported by the Saudi Ministry of Education, King Saud University, KSA (to SA) and The Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by SA and ARH. The first draft of the manuscript was written by SA, and all authors have commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.\u00a0<i>Code availability<\/i>\u00a0Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The datasets generated or analysed during the current study are included in this article and in its supplementary material files, which can be found in the online version of this article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}